ImmunoGen shakes off Morgan Stanley downgrade to trade higher

ImmunoGen (IMGN +9.8%) bounces back from early losses to trade sharply higher.

Early weakness was likely attributable to Morgan Stanley, where analysts downgraded the shares to Underweight with a $9.50 price target citing trouble with IMGN901.

See also: IMGN signs third licensing agreement with Novartis.

From other sites
Comments (1)
  • longimgn
    , contributor
    Comments (876) | Send Message
    results from ASH must have been released today from the West Coast and driven the shares higher, JMHO....... short lived rally.....JMHO
    11 Nov 2013, 06:12 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs